Skip to main content

Table 1 Clinical characteristics of subjects studied

From: Citrullinated histone H3, a marker of extracellular trap formation, is increased in blood of stable asthma patients

  Asthma n = 60 Controls n = 50 p-value
Age, years 50 (39–56) 45.5 (39–53) NS
Female gender 44 (73.7) 29 (58.0) NS
Height, m 1.63 (1.58–1.71) 1.65 (1.6–1.76) NS
Body mass index (BMI), kg/m2 26.9 (23.4–31.6) 26.4 (23.0–28.1) NS
History of smoking 18 (30.0) 17 (34.0) NS
Active smokers 7 (11.7) 8 (16.0) NS
Arterial hypertension 27 (45.0) 16 (32.0) NS
Diabetes mellitus 8 (13.3) 5 (10.0) NS
Hypercholesterolemia 17 (28.3) 16 (32.0) NS
Medications used:
 Inhaled corticosteroids 59 (98.3)   
 Long-acting β2-agonists 49 (81.7)   
 Montelukast 9 (15.0)   
 Oral corticosteroids 17 (28.3)   
Atopy 41 (68.3)   
Asthma duration, years 10 (5–15)   
Asthma control (according to Asthma Control Test results)
 Well-controlled (score > 19) 15 (25.0)   
 very poorly controlled (score > 16) 25 (41.7)   
Asthma severity (GINA):
 Mild 9 (15.0)   
 Moderate 21 (35.0)   
 Severe 30 (50.0)   
Prebronchodilator FEV1/VC, % 67.8 (59.4–75.9)   
Postbronchodilator FEV1/VC, % 73.1 (68.2–79.7)   
Postbronchodilator TLC, L
[% of predicted value]
5.76 (5.18–6.47)
[111.8 (103.3–119.8)]
  
Postbronchodilator RV, L
[% of predicted value]
2.23 (1.67–2.66)
[123.6 (108.3–147.2)]
  
  1. Categorical variables are presented as numbers (percentages), continuous variables as median (interquartile range)